CSIMarket
 
Regenxbio Inc   (RGNX)
Other Ticker:  
 
 
Price: $22.3300 $0.14 0.631%
Day's High: $22.609 Week Perf: 1.59 %
Day's Low: $ 21.25 30 Day Perf: 21.03 %
Volume (M): 523 52 Wk High: $ 28.80
Volume (M$): $ 11,685 52 Wk Avg: $18.13
Open: $22.13 52 Wk Low: $11.83



 Market Capitalization (Millions $) 980
 Shares Outstanding (Millions) 44
 Employees 300
 Revenues (TTM) (Millions $) 99
 Net Income (TTM) (Millions $) -261
 Cash Flow (TTM) (Millions $) -65
 Capital Exp. (TTM) (Millions $) 14

Regenxbio Inc
Regenxbio Inc is a leading biotechnology company, headquartered in Maryland, USA.
The company specializes in developing gene therapies for the treatment of genetic diseases.
Established in 2008, Regenxbio has quickly gained recognition for its innovative approach in the field of gene therapy.
The company uses proprietary viral vectors to deliver genes to specific cells in the body, aiming to correct the genetic defects that cause various diseases.
Regenxbioes gene therapy approach holds promise for the treatment of a range of genetic disorders, including rare diseases.
Regenxbio currently has several gene therapy candidates under development, targeting different disorders, including Angelman syndrome, Huntingtones disease, and retinal disorders.
The companyes lead candidate, RGX-314, is being developed for the treatment of wet age-related macular degeneration (AMD).
RGX-314 has already shown impressive results in clinical trials, demonstrating its potential as a game-changer for the treatment of AMD.
In addition to its gene therapy pipeline, Regenxbio has collaborations with several leading biotech and pharmaceutical companies.
These collaborations are aimed at leveraging Regenxbioes technology to develop new gene therapies for various indications, including neurodegenerative diseases and cancer.
Regenxbio has a team of experienced professionals, including scientists, researchers, and medical experts.
The companyes leadership team is composed of industry experts, and its board of directors includes renowned physicians, scientists, and business leaders.
Regenxbio has received significant funding from several venture capital firms and investors.
Overall, Regenxbio Inc is a promising biotechnology company that is at the forefront of developing gene therapies for the treatment of various genetic diseases.
With its strong pipeline of gene therapy candidates and collaborations with leading partners, the company is well-positioned for long-term growth and success.


   Company Address: 9804 Medical Center Drive Rockville 20850 MD
   Company Phone Number: 552-8181   Stock Exchange / Ticker: NASDAQ RGNX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Regenxbio Inc

Regenxbio Inc Sees Remarkable Rise in Earnings and Revenue During Q3 2023

Regenxbio Inc, a leading biotechnology company, has reported a significant improvement in its earnings per share (EPS) for the July to September 30, 2023, period. The EPS improved to $-1.41, a positive development compared to the prior year quarter and the preceding quarter.
In addition to the improved EPS, Regenxbio Inc also witnessed an increase in revenue. The company's revenues for the period increased by 9.06% to $28.91 million, compared to $26.51 million in the same quarter last year. This growth in revenue is a positive sign for the company and indicates a favorable performance during the period.

Regenxbio Inc

Significant Revenue Decline Witnessed in Regenxbio Inc's Fiscal Year-End Report as of June 30, 2023

Regenxbio Inc, a biotechnology company, has shown increasing deficits and declining revenues in the fiscal time-frame ending June 30, 2023. The company's deficit per share increased from $-1.58 to $-1.66 compared to the previous year, and the deficit also grew from $-1.53 in the preceding financial reporting period. This trend indicates financial instability and raises concerns about the company's ability to generate profit.
Moreover, Regenxbio Inc experienced a significant decline in revenue, with a staggering decrease of -38.813%, dropping from $32.65 million in the same period the previous year to $19.98 million. Although the revenue did show a slight sequential increase of 4.384% from $19.14 million, it remains significantly lower than previous years. This decline in revenue suggests a struggling business environment or a decrease in demand for the company's products or services.






 

Regenxbio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com